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Background: Targeting drugs to their sites of action to overcome the systemic side effects 
associated with most antineoplastic agents is still a major challenge in pharmaceutical research. 
In this study, the monoclonal antibody, trastuzumab, was used as a targeting agent in nanopar-
ticles carrying the antitumor drug, doxorubicin, specifically to its site of action.
Methods: Chitosan-doxorubicin conjugation was carried out using succinic anhydride as 
a crosslinker. Trastuzumab was conjugated to self-assembled chitosan-doxorubin conjugate 
(CS-DOX) nanoparticles (particle size, 200 nm) via thiolation of lysine residues and subsequent 
linking of the resulted thiols to chitosan. Conjugation was confirmed by gel permeation 
chromatography, differential scanning calorimetry, Fourier transform infrared spectroscopy, and 1H 
nuclear magnetic resonance spectroscopy studies. Dynamic light scattering, transmission electron 
microscopy, and zeta potential determination were used to characterize the nanoparticles.
Results: CS-DOX conjugated nanoparticles had a spherical shape and smooth surface with a 
narrow size distribution and core-shell structure. Increasing the ratio of doxorubicin to chitosan 
in the conjugation reaction gave rise to a higher doxorubicin content but lower conjugation 
  efficiency. Trastuzumab-decorated nanoparticles (CS-DOX-mAb) contained 47 μg/mg 
doxorubicin and 33.5 μg/mg trastuzumab. Binding of trastuzumab to the nanoparticles was 
further probed thermodynamically by isothermal titration calorimetry. Fluorescence microscopy 
demonstrated enhanced and selective uptake of CS-DOX-mAb by Her2+ cancer cells compared 
with nontargeted CS-DOX nanoparticles and free drug.
Conclusion: Antibody-conjugated nanoparticles were shown to discriminate between Her2+ 
and Her2− cells, and thus have the potential to be used in active targeted drug delivery, with 
reduction of drug side effects in Her2+ breast and ovarian cancers.
Keywords: chitosan, doxorubicin, self-assembled nanoparticles, active targeting, 
trastuzumab
Introduction
The main objective in anticancer drug development is to deliver therapeutic agents in 
a targeted and selective fashion to their site of action, and to decrease adverse effects 
and enhance efficacy. Over recent years, nanoparticulate carrier systems have aroused 
ever increasing interest in this area.1,2 These targeted nanosystems can deliver drugs 
in a passive or active way. Passive targeted drug delivery takes advantage of the poor 
lymphatic systems of tumor tissues and their leaky vasculature with pore sizes rang-
ing from 100 to 780 nm.3–5 These characteristics enable what is called the “enhanced 
permeability and retention” effect, which allows enhanced deposition of delivery 
nanovehicles at the site of a solid tumor. Active targeted drug delivery on the other 
hand is achieved via covalent conjugation of targeting molecules on the nanoparticle International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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surface which can recognize and bind to specific ligands 
expressed specifically in cancer cells. One such ligand is 
human epidermal growth factor receptor 2 (Her2) or ErbB2 
(Neu), the expression of which is amplified in about 30% of 
breast cancers and 20% of ovarian cancers, and this receptor 
is expressed weakly in normal adult tissues.6–8
Trastuzumab (Herceptin®) is a humanized monoclonal 
antibody directed against the Her2 receptor, and is the only 
Her2-targeted therapy approved by the US Food and Drug 
Administration for the treatment of advanced breast cancer. 
Combination of trastuzumab with conventional chemo-
therapy leads to increased response rates in comparison with 
trastuzumab alone.9–11 In addition, according to some clini-
cal trials, anthracycline-based chemotherapy demonstrated 
more successful results in Her2+ women.12 However, trastu-
zumab has been shown to aggravate anthracycline-induced 
cardiotoxicity, and thus cannot be given concomitantly with 
anthracyclines, including doxorubicin.13,14 Conjugation of 
trastuzumab to doxorubicin-carrying nanoparticles allows 
transport of the chemotherapeutic agent specifically to 
tumor cells and reduced their adverse cardiotoxic effects. 
Furthermore, in such nanoparticulate formulations, trastu-
zumab is intended to act as a targeting ligand rather than as 
a therapeutic agent and thus its concentration is far below 
its therapeutic dose. Previous studies have shown promising 
results for either cancer therapy or imaging via trastuzumab 
decoration of such nanoparticles as dextran iron oxide 
nanoparticles,15 poly(d,l-lactide-co-glycolide)/montmoril-
lonite nanoparticles,16 poly(dl-lactic acid) nanoparticles,17 
and human serum albumin nanoparticles.18–20
Chitosan is a carbohydrate polymer with the desirable 
properties of biodegradability and biocompatibility that have 
made it a candidate polymer for preparation of drug delivery 
carriers.21–29 Several methods have been developed for the prep-
aration of doxorubicin delivery systems based on chitosan,30 
which include dextran sulfate-chitosan hydrogel nanoparticles, 
glycol-chitosan nanoaggregates, oleoyl-chitosan nanoparticles, 
chitosan-poly(acrylic acid) hollow nanospheres, and stearic 
acid-grafted chitosan oligosaccharide micelles.
However, in targeted delivery systems, covalent con-
jugation of drug to its carrier is more advantageous than 
drug encapsulation because it prevents premature drug 
release into the blood circulation before its delivery to the 
target site. In this study, chitosan-doxorubicin conjugate 
(CS-DOX) nanoaggregates were prepared via covalent 
conjugation of doxorubicin to chitosan. Trastuzumab was 
conjugated to the nanoaggregates, and the efficacy of 
the resulting actively targeted nanocarriers was studied 
in vitro.
Methods and materials
Materials
Doxorubicin (purity approximately 98.5%) was purchased 
from RPG Life Sciences Ltd (Ankleshwar, India). Chitosan, 
with a medium molecular weight and deacetylation of about 
96%, was supplied by Fluka, Germany. Sodium nitrite, 
hydrochloric acid, glacial acetic acid, sodium hydroxide, 
succinic anhydride, 1-ethyl-3-(3-dimethyl amino-propyl) 
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), acetonitrile, triethylamine, and ethyl acetate and 
chloroform (analytical grade) were obtained from Merck, 
Darmstadt, Germany. Total protein kit (product code TP0200) 
and sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-
1-carboxylate were purchased from Sigma (St Louis, MO). 
Trastuzumab was purchased from Roche,   Mannheim, 
Germany. Cell lines were provided by the Pasteur Institute, 
Tehran, Iran. All other chemicals were of analytical grade. 
Deionized water was used throughout.
conjugation of doxorubicin to chitosan
CS-DOX conjugates were synthesized using succinic 
anhydride as a spacer. Succinic anhydride was employed to 
react with and convert the amine group of doxorubicin to 
carboxylic residues, ie, succinic acid residues. The resulted 
succinyl doxorubicin (SDOX) was then introduced to chitosan 
via amide bond formation mediated by EDC and NHS.
At first, 120 kDa chitosan was prepared according to 
the depolymerization method described by Peniston and 
Johnson.31 Briefly, 10 mL nitrite sodium solution (1 mg/mL) 
was added to 100 mL 2% (w/v) chitosan solution in 6% (v/v) 
acetic acid. The depolymerization reaction was allowed to 
proceed for 1 hour while stirring and was then stopped by 
raising the pH to 9 using 5 N NaOH. The precipitated white-
yellowish chitosan was then filtered and washed thoroughly 
with acetone. The filtrate was redissolved in a minimum 
volume of acetic acid 0.1 N and was dialyzed against deion-
ized water (2 × 2 L for 90 minutes and 1 × 2 L overnight). 
The dialyzed product was lyophilized at 50°C and 0.01 mbar 
(LyoTrap plus, LTE Scientific, Chorley, UK).
To prepare SDOX, 40 mg doxorubicin HCl was dissolved 
in dry acetonitrile to which 70 µL triethylamine and 690 mg 
succinic anhydride in 3 mL dry acetonitrile was added. The 
reaction was allowed to complete by 15 hours stirring at 4°C 
in the dark. Afterwards, the solution was distributed between 
10 mL sodium bicarbonate 5% (w/v) solution and 40 mL 
chloroform. The chloroform phase was decanted and the 
residual solution was extracted by ethyl acetate after lowering 
the pH using 1 M HCl. Ethyl acetate was evaporated by a 
rotary evaporator to obtain SDOX.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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For covalent conjugation of SDOX to chitosan, 200 mg 
chitosan was hydrated in 2 mL of 1 M HCl. Deionized water 
was added to give a final chitosan concentration of 1% (w/v). 
SDOX in 2% sodium bicarbonate was added to obtain an 
SDOX/CS (w/w) ratio of 20%, 10%, 5%, 2.5%, and 1%, 
followed by addition of EDC and NHS (5 molar equivalents 
with respect to SDOX). pH was adjusted to 6.6 using 5 N 
NaOH and the reaction was allowed to stir for 36 hours 
at room temperature. Afterwards, unreacted components 
were removed by extensive dialysis against deionized 
water.   CS-DOX was concentrated via centrifugation with 
30 kDa cutoff centrifugal ultrafilters (Millipore Corporation, 
  Billerica, MA) at 4000 g and 10°C for 15 minutes. The 
CS-DOX were stored at 4°C until further use (Figure 1).
Conjugates with an initial CS-DOX (w/w) ratio of 20%, 
10%, 5%, 2.5%, and 1% were named as CS-DOX-1, CS-DOX-2, 
CS-DOX-3, CS-DOX-4, and CS-DOX-5, respectively.
gel permeation chromatography
The molecular weight of the depolymerized chitosan was deter-
mined by gel permeation chromatography. A PL Aquagel-OH 
mixed gel filtration column (300 mm × 7.5 mm internal diam-
eter, pore size 8 µm) from Agilent Technologies, Santa Clara, 
CA, was used. All chromatograms were generated on an Agilent 
1100 liquid chromatographer (Agilent Technologies), and the 
eluting fraction was monitored using a refractive index signal 
detector. The lyophilized powder of depolymerized chitosan 
was dissolved in 300 mM acetate buffer, pH 4.5, with a final 
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Figure 1 schematic illustration of the procedures for the synthesis of chitosan-doxorubicin conjugate.
Abbreviations: eDc, 1-ethyl-3-(3-dimethyl amino-propyl) carbodiimide hydrochloride; Nhs, N-hydroxysuccinimide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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concentration of 3 mg/mL, and was chromatographed at a flow 
rate of 5 mL/min. Chromatograms were generated and analyzed 
by EZChrom Elite software (Version 3.1, Scientific Software, 
Pleasanton, CA) using the narrow method. Gel permeation 
chromatography analysis was also carried out to examine 
covalent conjugation of doxorubicin to chitosan.
Fourier transform infrared spectroscopy
To study the chemical reactions between doxorubicin and 
succinic anhydride, doxorubicin and rotary-dried SDOX were 
pressed into KBr discs and examined by Fourier transform 
infrared spectroscopy using a Nicolet spectrometer (Nicolet 
Magna IR 550, Madison, WI).
1h nuclear magnetic resonance 
spectroscopy
1H nuclear magnetic resonance (NMR) spectra were recorded 
on a Bruker FT-80 spectrometer (Bruker, Rheinstetten, 
  Germany) and chemical shifts (δ) are in parts per million 
(ppm) relative to internal tetramethylsilane. To this end, 
CDCl3 was used as the solvent for SDOX while doxorubicin, 
chitosan, and CS-DOX were dissolved in D2O.
Differential scanning calorimetry
The thermal behavior of CS-DOX was studied by differential 
scanning calorimetry using a 822e differential scanning calo-
rimeter (Mettler-Toledo, Greifensee, Switzerland). Samples 
were purged with dry nitrogen at a flow rate of 10 mL/min 
and were heated in the temperature range 25°C–450°C at a 
heating rate of 10°C/min.
Preparation of self-assembled 
nanoparticles
CS-DOX conjugates were dissolved in deionized water at a 
concentration of 5 mg/mL, and were gently stirred for one 
hour at room temperature. In addition, effect of concentra-
tion of conjugate was investigated by preparation of self-
assembled nanoparticles using different concentrations of 
CS-DOX-2 (0.25, 1, 5, 10, and 20 mg/mL).
Determination of conjugation efficiency 
and drug content
Five hundred microliters of concentrated conjugates were 
placed on cover slips and dried in an oven (Memmert INB 
400, Schwabach, Germany) at 50°C for three hours. The cover 
slips were weighed afterwards, and knowing the initial weight 
of  the cover slip, the mg of  the conjugates was calculated. Quan-
tification of doxorubicin was achieved via   spectrophotometry 
at 480 nm (Scinco S-3100, Seoul, Korea). The conjugation 
efficiency and doxorubicin content of the CS-DOX conjugates 
was determined applying the following equations:
 
Conjugation
efficiency(%)
=
weightof drugfoundconjugated
weighto of totaldrugused
100 ×
 
 
Drugcontent
(%w/w) =
weight of drug foundconjugated
weightof con njugate
100 ×
 
Measurement of particle size, 
polydispersity, and zeta potential
The hydrodynamic mean diameter, polydispersity index, 
and zeta potential of the nanoparticles were measured by 
dynamic light scattering and laser Doppler electrophoresis 
using a Zetasizer (Nano-ZS, Malvern, Worcestershire, UK). 
All dynamic light scattering measurements were performed 
at a wavelength of 633 nm at 25°C with an angle detection 
of 90°. All measurements were done in triplicate.
scanning electron microscopy
The surface morphology of the nanoparticles was imaged 
using a scanning electron microscope (XL 30, Philips, 
Eindhoven, the Netherlands). One drop of the nanoparticle 
preparation was layered on the scanning electron microscope 
stub and allowed to dry in air at room temperature. The dried 
nanoparticles were then coated with gold metal using a sput-
ter coater (SCD 005, Bal-Tec, Balzers, Switzerland).
Transmission electron microscopy
A transmission electron microscope (CEM 902A, Zeiss, 
Oberkochen, Germany) was used to get a better idea of the 
inner structure of the self-assembled nanoparticles. The 
nanoparticle suspension was deposited on copper grids, 
subsequently negatively stained using 0.5% phosphotungstic 
acid, air dried, and viewed under the transmission electron 
microscope.
Thiolation of trastuzumab and 
quantification of immobilized thiol groups
Trastuzumab thiolation was carried out using a 100-fold molar 
excess of 2-iminothiolane (Traut’s reagent). The trastuzumab 
monoclonal antibody was prepared in 50 mM phosphate buffer 
(pH 8) containing NaCl 0.15 M. To each 5 mL of trastuzumab 
solution (2 mg/mL), 458 µL Traut’s reagent (2 mg/mL) was 
added. The thiolation reaction was stirred gently for 2 hours 
at room temperature. Unreacted Traut’s reagent was excluded 
by centrifugation three times with 30 kDa cutoff centrifugal International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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ultrafilters (Millipore   Corporation) at 4000 g and 10°C for 
15 minutes.
The number of thiol groups added to the monoclonal 
antibody was subsequently dosed by Ellman’s test as follows. 
The Ellman reagent, with a final concentration of 10 mM, was 
dissolved in 0.1 M phosphate buffer (pH 8). Ellman’s reagent 
100 µL was added to 400 µL of 2 mg/mL monoclonal antibody 
solution in phosphate buffer (0.1 M, pH 8). After 15 minutes 
of incubation, the absorbance was measured at 450 nm using 
a spectrophotometer (Scinco S-3100). A standard calibration 
curve was obtained from 10–200 µM N-acetyl L-cysteine.
Preparation of trastuzumab-modified 
nanoparticles
CS-DOX-2 nanoparticles were dispersed in phosphate buffer 
(0.1 M, pH 7.2) at a concentration of 5 mg/mL and were 
activated using 2 mg of the heterobifunctional crosslinker, 
sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane-
1-carboxylate. After 3 hours of incubation at room 
temperature, sulfhydryl-reactive nanoparticles were purified 
by centrifugation (4000 g, 10°C, 15 minutes) using 100 kDa 
cutoff centrifugal ultrafilters (Millipore   Corporation). 
The coupling reaction was achieved by adding 500 µL of 
thiolated trastuzumab 2 mg/mL to 4 mL nanoparticle sus-
pension 5 mg/mL, followed by three hours of incubation at 
room temperature. The trastuzumab-modified nanoparticles 
(CS-DOX-mAb) were purified by centrifugation (26,000 rpm, 
10°C, 30 minutes) and nonconjugated antibody in supernatant 
was quantified with using the Total Protein Kit (Micro Lowry, 
Onishi and Barr modification, Sigma).
Isothermal titration calorimetry study
Isothermal titration calorimetry experiments were conducted 
using an isothermal titration calorimetry instrument (VP-
ITC, MicroCal, Northampton, MA). The titration vessel was 
made from stainless steel. Trastuzumab solution (39 nM) 
was injected using a Hamilton syringe into the calorimetric 
titration vessel which contained 1.8 mL protein A 8.86 nM. 
Thin (0.15 mm inner diameter) stainless steel hypodermic 
needles, permanently fixed to the syringe, reached directly 
into the calorimetric vessel. Injection of the trastuzumab 
solution into the perfusion vessel was repeated 30 times, with 
10 µL per injection. The calorimetric signal was measured by 
a digital voltmeter which was part of a computerized record-
ing system. The heat of each injection was calculated by the 
MicroCal Origin 7.0 software supplied with the instrument. 
The microcalorimeter was frequently calibrated electrically 
during the course of the study.
cell lines and culture conditions
The Her2− human breast cancer cell line (MCF7) and Her2+ 
ovarian carcinoma cell line (SKOV-3) were obtained from 
National Cell Bank of Iran (Pasteur Institute). Cells were 
maintained in RPMI-1640 culture medium supplemented 
with fetal bovine serum 10%, penicillin 100 units/mL, 
and streptomycin 100 ng/mL at 37°C in a 5% CO2 humidified 
incubator (New Brunswick Scientific, Edison, NJ).
In vitro cytotoxicity assay
The cytotoxicity of CS-DOX-2, CS-DOX-mAb, and free 
doxorubicin against SKOV-3 cells was evaluated using the 
tetrazolium-based colorimetric (MTT) assay. The tested con-
centrations were 8, 40, and 200 nM doxorubicin equivalents. 
Cytotoxicity was then measured after 48 hours of exposure 
using the MTT method.
Specificity of trastuzumab-modified 
nanoparticles
The specificity of the trastuzumab-modified nanoparticles was 
investigated by comparing cellular uptake of CS-DOX-mAb 
into Her2-overexpressing SKOV-3 cells and Her2− MCF-7 cells. 
Cells were seeded in eight-well chamber slides and treated with 
CS-DOX-2, CS-DOX-mAb, and free doxorubicin at a concen-
tration of 200 nM doxorubicin equivalents. After 24 hours of 
incubation at 37°C in a humidified 5% CO2 atmosphere, the 
medium was removed, the cells were fixed with methanol/
acetone (v/v 9:1) at 4°C for 30 minutes, rinsed in phosphate-
buffered saline, and observed under a fluorescence micro-
scope with a green filter (λext 490 nm and λem 520 nm) and 
1000 msec exposure time (BX40, Olympus, Tokyo, Japan).
Results
Drug content and conjugation efficiency
Doxorubicin was conjugated to chitosan using a succinic 
anhydride crosslinker. The drug content and conjugation 
efficiency of the prepared conjugates are shown in Table 1.
Fourier transform infrared and 1h NMr 
spectroscopic study
Fourier transform infrared and 1H NMR spectra of doxorubicin, 
SDOX, and CS-DOX conjugates are depicted in Figure 2A, 2B, 
and 2C. Observed signals for 1H-NMR of doxorubicin were:
1H NMR (DMSO- d6): 7.90- 7.92 (M, 2H, H3, H4), 7.64 
(d, J = 7.2, 1H, H2), 5.30 (S,1H, H11), 4.93 (bs, 1H, H1), 4.58 
(S, 2H, CO- CH2- OH), 4.17 (m, 1H), 3.93 (S, 3H, OCH3), 
2.32 (1H), 2.92 (m, 2H), 2.14 (m, 2H), 1.92 (m, 1H), 1.69 
(m, 1H), 1.18 ( d, 3H, CH3).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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calorimetric study of cs-DOX 
conjugation
Thermograms of doxorubicin, chitosan, and CS-DOX are 
presented in Figure 3. A sharp endothermic peak located 
at 100°C was seen in all differential scanning calorimetry 
  diagrams. The differential scanning calorimetry thermo-
gram of chitosan showed another endothermic peak at 
180°C and an exothermic peak at 370°C. Doxorubicin was 
characterized by a relatively sharp endothermic peak at 
200°C followed by two other endothermic peaks at higher 
  temperatures. The differential scanning calorimetry curve for 
the CS-DOX conjugates exhibited an endotherm at 160°C 
and an exotherm at 340°C.
gel permeation chromatograms
Gel permeation chromatograms of chitosan and CS-DOX-2 are 
shown in Figure 4. Analysis of the resulting chromatograms using 
a narrow method revealed the molecular weights of chitosan and 
CS-DOX-2 to be 115.644 and 119.937 kDa, respectively.
size, zeta potential, and polydispersity 
index of cs-DOX nanoparticles
All the prepared CS-DOX conjugated but CS-DOX-1 self-
assembled into particles, the size, zeta potential, and 
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Figure 2 (A) Fourier transform infrared spectrum of doxorubicin and succinyl doxorubicin. (B) 1h nuclear magnetic resonance spectrum of doxorubicin and succinyl 
doxorubicin. (C) 1h nuclear magnetic resonance spectrum of chitosan and chitosan-doxorubicin conjugate.
Table 1 Drug content and conjugation efficiency of different 
chitosan-doxorubicin conjugates
Conjugation  
efficiency
Drug  
content
DOX used/ 
CS (w/w)
Conjugate
33% 6.7% 20% cs-DOX-1
41% 4.1% 10% cs-DOX-2
54.6% 2.37% 5% cs-DOX-3
62% 1.55% 2.5% cs-DOX-4
69% 0.69% 1% cs-DOX-5
Abbreviations: cs, chitosan; DOX, doxorubicin.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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polydispersity indexes for which are given in Table 2. In 
addition, the effect of conjugate concentration on size of the 
prepared nanoparticles was investigated for CS-DOX-2, and 
the resulting data are shown in Figure 5.
surface and inner morphology  
of nanoparticles
Scanning electron microscopic images as depicted in 
  Figure 6A revealed spherical and smooth-surfaced nanopar-
ticles with a uniform size distribution. In addition, according 
to the transmission electron microscopic images, the inner 
morphology of CS-DOX self-assembled nanoparticles con-
sists of a core-shell structure (Figure 6B).
Trastuzumab coupling to cs-DOX 
nanoparticles
Thiol groups required for the coupling reaction were added 
to trastuzumab by use of 2-iminothiolane. According to the 
Ellman’s test, 12.33 reactive thiol groups were linked to the 
lysine residues of the monoclonal antibody, which is equal to 
13.7% of the lysine residues available.   Furthermore, under the 
experimental conditions used, 67% of the monoclonal anti-
body molecules were attached to CS-DOX-2 nanoparticles. 
Each gram of the CS-DOX-mAb formulation obtained thus 
consisted of 47 µg doxorubicin and 33.5 µg trastuzumab.
Interaction of nanoparticle-conjugated 
trastuzumab with protein A
Conjugation of the monoclonal antibody to the nanoparticles 
was analyzed by isothermal titration calorimetry taking 
advantage of the ability of the Fc fragment of an immuno-
globulin molecule to interact with protein A. Isothermal 
titration calorimetry thermograms of protein A with free 
antibody and nanoparticle-conjugated monoclonal antibody 
are shown in Figure 7.
According to data analyzed by MicroCal Origin 7.0 soft-
ware, the free monoclonal antibody-protein A interaction 
fitted well into a one-binding site model, while the conju-
gated monoclonal antibody-protein A interaction resulted 
in a minimum Chi-square value when the two-binding site 
model was applied. Thermodynamic parameters derived from 
corresponding models have been summarized in Table 3. The 
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Figure 3 Differential scanning calorimetry thermograms of chitosan, doxorubicin 
and chitosan-doxorubicin conjugate (cs-DOX-2).
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Figure  4  gel  permeation  chromatogram  of  (A)  chitosan  and  (B)  chitosan-
doxorubicin conjugates.
Table  2  size,  zeta  potential,  and  polydispersity  index  of 
nanoaggregates prepared from different chitosan-doxorubicin 
conjugates
PDI Zeta potential  
(mV)
Size (nm) Drug  
content
Conjugate
0.108 ± 0.054 16.5 ± 3 228 ± 21 4.1% cs-DOX-2
0.173 ± 0.041 17.5 ± 4 346 ± 37 2.37% cs-DOX-3
0.083 ± 0.047 14.3 ± 1 493 ± 26 1.55% cs-DOX-4
0.253 ± 0.023 18.1 ± 4 671 ± 18 0.69% cs-DOX-5
Abbreviations: cs-DOX, chitosan-doxorubicin conjugate; PDI, polydispersity index.
Figure 5 effect of chitosan-doxorubicin conjugate concentration on hydrodynamic 
diameter of nanoaggregates.
Abbreviation: cs-DOX, chitosan-doxorubicin conjugate.
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affinity constant (Ka), enthalpy changes (∆H), and binding 
stoichiometry (n) of the interaction were used to determine 
the change in Gibb’s free energy (∆G) and change in entropy 
(∆S) for each interaction event.
cytotoxicity assay
The results of the cell viability MTT assay as presented 
graphically in histograms demonstrated increased cytotoxic 
activity of CS-DOX-mAb compared with CS-DOX-2. 
  However, the growth inhibitory activity of doxorubicin in 
the CS-DOX-mAb formulation was reduced with respect 
to the equivalent concentration of free drug. Such differ-
ences were slightly more apparent for higher doses of drug 
(Figure 8).
cellular uptake
Selective uptake of trastuzumab-modified nanoparticles by 
Her2+ cells was investigated by fluorescence microscopy 
utilizing the red fluorescence of doxorubicin. CS-DOX-mAb 
showed significantly higher entry into the Her2-overexpress-
ing cell line, SKOV3, compared with the control MCF-7 cell 
line. Nontargeted nanoparticles, on the other hand, showed 
no obvious difference in this regard (Figure 9).
Discussion
This study aimed to develop a targeted delivery system 
for delivery of the chemotherapeutic drug, doxorubicin, to 
Her2-overexpressing cancer cells. CS-DOX conjugates were 
synthesized via carboxylation of doxorubicin and subsequent 
amidation of SDOX with amine groups on chitosan.
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Figure 7 Isothermal titration calorimetry thermograms for interactions of protein A with (A) free antibody and (B) antibody attached to nanoparticles.
B A
Figure 6 (A) scanning electron micrographs of chitosan-doxorubicin conjugate 
(cs-DOX-2)  nanoparticles  and  (B)  transmission  electron  micrographs  of  cs-
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Table  3  Interaction  thermodynamic  parameters  of  protein 
A with free and attached antibody
Nanoparticle-conjugated  
monoclonal antibody
Free  
monoclonal  
antibody
Parameter
Second  
binding site
First  
binding site
1.07 ± 0.261 1.65 ± 0.099 2.78 ± 0.469
an
203.6 348.1 5.71 bK (×10−4 M−1)
+68.1 −93.9 −104.8 c∆H°(kcal/mol)
−8.664 −10.162 −6.96 d∆G°(kcal/mol)
+0.318 −0.281 −0.330 e∆S°(kcal/mol/°K)
Notes: abinding stoichiometry;  baffinity constant;  cmolar enthalpy change for the 
binding; dmolar free energy change; emolar entropy change.
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Figure 8 effect of doxorubicin, chitosan-doxorubicin conjugated nanoparticles, and trastuzumab-decorated chitosan-doxorubicin conjugated nanoparticles at different 
concentrations on viability of sKOV-3 cell line.
Abbreviations: cs, chitosan; DOX, doxorubicin; NP, nanoparticles.
The appearance of peaks at 2.9 ppm and 3.3 ppm in the 
1H NMR spectrum for SDOX indicates the presence of a 
-CH2-CH2 group in addition to peaks belonging to the pro-
tons of doxorubicin (Figure 2B). Furthermore, appearance of 
new bands at around 1689 cm−1 which related to a carbonyl 
group (C=O) compared with that of the carbonyl group in 
doxorubicin (1728 cm−1) is attributed to the carbonyl group 
in succinate (Figure 2A).
Amide binding of SDOX to chitosan was carried out 
using EDC/NHS reagents. Conjugation was confirmed by gel 
permeation chromatography, differential scanning calorim-
etry, Fourier transform infrared spectroscopy, and 1H NMR 
studies. Gel permeation chromatography as   presented in 
Figure 4 shows the increase in molecular weight of   chitosan 
upon conjugation of doxorubicin moieties, and thus verifies 
the chemical nature of CS-DOX binding. In addition to 
peaks related to aliphatic protons in chitosan, the 1H NMR 
spectrum of CS-DOX conjugate showed the appearance of 
aromatic protons of doxorubicin at 5.4 ppm and 8.3 ppm 
plus its methyl group at 1.17 ppm. Differential scanning 
calorimetry analysis of chitosan, doxorubicin, and CS-DOX 
conjugates was also carried out (Figure 3). A sharp peak at 
100°C present in all three thermograms is attributed to the 
evaporation of humidity absorbed by the specimen. The 
differential scanning calorimetry thermogram of chitosan 
showed an endothermic peak at 180°C and an exothermic 
peak at 370°C which are ascribed, respectively, to hydrogen-
bonding dissociation and degradation of this polymer.32,33 
The differential scanning calorimetry plot obtained for 
doxorubicin revealed an endothermic melting peak at 200°C 
with endothermic peaks of degradation appearing at higher 
temperatures. Conjugation of doxorubicin to chitosan led 
to a shift in hydrogen-bonding dissociation and degradation 
peaks of chitosan, while no trace of the doxorubicin peaks 
was observed in the differential scanning calorimetry ther-
mogram of CS-DOX. The differential scanning calorimetry 
experiments thus corroborate conjugation of CS and DOX. 
In fact, addition of hydrophobic and voluminous doxorubicin 
molecules to the glucosamine units of chitosan weakens International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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the hydrogen binding between these units and renders the 
dissociation temperature lower. The absence of differential 
scanning calorimetry peaks for doxorubicin in the thermo-
gram of CS-DOX confirms that no free drug exists in the 
CS-DOX conjugate.
Increasing the ratio of doxorubicin to chitosan in the 
conjugation reaction gave rise to a higher doxorubicin con-
tent but lower conjugation efficiency. All in all, CS-DOX 
conjugates with drug contents of 0.7%, 1.6%, 2.7%, 4.1%, 
and 6.7% were synthesized. The amphiphilic property of 
CS-DOX conjugates in which the hydrophobic   doxorubicin 
molecule is attached to the hydrophilic chitosan chain 
enables their self-assembly into nanoparticles. Such nano-
aggregation behavior has been previously reported by Son 
et al and Hyung Park et al for glycol chitosan-doxorubicin 
conjugates.34,35 The exception is CS-DOX-1, the high 
doxorubicin content of which confers too high a degree of 
hydrophobicity, which leads to its precipitation in aqueous 
medium. Figure 10 is a schematic illustration of the self-
assembly of CS-DOX conjugates, which is in accordance 
with the core-shell structures observed in transmission 
electron micrographs (Figure 6B).
AB
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Figure 9 Fluorescence microscopy of cellular uptake of (A) trastuzumab-decorated chitosan-doxorubicin conjugated nanoparticles by sKOV-3 cell line, (B) trastuzumab-
decorated chitosan-doxorubicin conjugated nanoparticles by McF-7 cell line, (C) chitosan-doxorubicin conjugated nanoparticles by sKOV-3 cell line, and (D) chitosan-
doxorubicin conjugated nanoparticles by McF-7 cell line. (E) sKOV-3 cells and (F) McF-7 cells in cell culture medium served as negative controls.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Scanning electron microscopic imaging also revealed 
smooth-surfaced and spherical nanoparticles with a narrow 
size distribution. The polydispersity index was determined to 
be satisfactorily low in nanoaggregates of all CS-DOX con-
jugates. The zeta potential showed no significant difference 
between the different types of conjugates, while the hydrody-
namic diameter of the nanoparticles was measured to be larger 
in conjugates with higher drug content. In fact, hydrophobic 
interactions between the drug-bearing parts of the conjugates 
and hydrogen bonding between the bare carbohydrate skeleton 
and surrounding water molecules are the main contributing 
forces involved in self-assembly of CS-DOX conjugates. 
With higher drug contents, more portions of the conjugate 
chain take part in inner hydrophobic interactions and cause 
more compact aggregation of conjugates and consequently a 
smaller nanoaggregate size. In addition, the concentration of 
chitosan-drug conjugate showed no significant effect on size 
of the nanoaggregates. This indicates the micelle-like nature 
of these aggregates as the thermodynamics governing the 
packing of micellar structures have been shown to make the 
size of spherical micelles independent of concentration.
Size of the drug carriers plays a key role in their 
  pharmacokinetics; the larger the nanoparticles, the higher the 
probability of their scavenging and clearance by macrophages. 
Nanoparticles larger than 300 nm activate the complement 
system and are cleared from the blood. Taking this into con-
sideration, small-sized CS-DOX-2 nanoaggregates were used 
for the conjugation of trastuzumab, the targeting ligand.
Trastuzumab  was  conjugated  to  self-assembled 
  CS-DOX-2 nanoparticles via thiolation of lysine residues 
by 2-iminothiolane and subsequent linking of the resulting 
thiols to amine groups on chitosan. The targeted nanoparticles 
obtained contained 47 μg/mg doxorubicin and 33.5 μg/mg 
trastuzumab. Trastuzumab decoration led to no significant 
change in size or zeta potential of the nanoparticles, and 
the attached trastuzumab is embedded among the dynamic 
conjugate chains and so does not affect nanoparticle size.
Binding of trastuzumab to the nanoparticles was further 
probed thermodynamically by an isothermal titration 
calorimetry study of the interaction of protein A with free and 
attached trastuzumab. Protein A is a 40–60 kDa surface protein 
originally found in the cell wall of Staphylococcus aureus, 
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and binds with the Fc region of antibodies. This polypeptide 
chain consists of five homologous IgG-binding domains 
(from the N-terminus; E, D, A, B, and C).36 However, steric 
hindrance restricts concomitant access of all five binding 
sites to the antibodies.37 The isothermal titration calorimetry 
study gave a binding ratio of 3 mol antibody/mol protein A. 
The trastuzumab attached generated an isothermal titration 
calorimetry profile different from that of the free antibody, 
which confirms covalent conjugation of trastuzumab to nano-
particles. The isothermal titration calorimetry profile for the 
free trastuzumab-protein A interaction was composed of nega-
tive exothermic peaks. However, the interaction between the 
attached trastuzumab and protein A revealed initial exothermic 
peaks followed by exothermic peaks. A similar isothermal 
titration calorimetry thermogram was observed by Coles et al 
for the interaction of dendrimers with DNA.38 According to 
this group, the endothermic part of the thermogram is related 
to the precipitation of the dendrimer-DNA complex. Here, 
interaction of protein A with the trastuzumab attached led to an 
opaque appearance in the solution which clearly demonstrated 
the occurrence of aggregation and precipitation in the system. 
Attachment of several trastuzumab monoclonal antibodies 
to each nanoparticle along with the capacity of each protein 
A to bind to more than one monoclonal antibody brings the 
nanoparticles in close proximity to each other and leads to 
their aggregation into a macrostructure which precipitates 
(Figure 11).
Furthermore, the initial endothermic peaks demonstrate 
that the FC fragment of the attached trastuzumab monoclo-
nal antibody has enough freedom to interact with protein A. 
This property may be taken advantage of for purification 
of such targeted delivery systems, using protein A affinity 
chromatography or for determination of monoclonal antibody 
on the surface of nanoparticles by techniques like surface 
plasmon resonance.39
In vitro cytotoxicity evaluation showed reduced efficacy 
of the CS-DOX nanoparticles with respect to free drug. This 
may be attributed to covalent and irreversible conjugation of 
doxorubicin to chitosan via a succinic anhydride crosslinker, 
as stated elsewhere.40,41 Free doxorubicin can penetrate the 
nuclear envelope, localize in nucleus and exert its cytotoxic-
ity through its primary mechanism of action, ie, inhibition 
of topoisomerase II. However, when conjugated to chitosan, 
doxorubicin cannot access its target and consequently its 
cytotoxic efficiency is hampered.
On the other hand, fluorescence microscopy displayed 
enhanced and selective uptake of CS-DOX-mAb by Her2+ 
cancer cells comparing with CS-DOX nontargeted nanoparti-
cles. The enhanced cellular uptake partially compensated for 
the diminished effect of attached doxorubicin and improved 
the cytotoxicity of this doxorubicin nanodelivery system.
Conclusion
A novel, chitosan-based targeted drug delivery system has 
been developed. The anti-HER2 humanized antibody, tras-
tuzumab, was used as the targeting moiety. The resulting 
amphiphilic polymer-drug conjugates with a doxorubicin 
content of 0.69%–4.1% (w/w) were demonstrated to self-
assemble into nanoparticles ranging from 200–700 nm in 
size depending on the doxorubicin content of the conjugate. 
Although covalent conjugation of doxorubicin to chitosan 
weakens its anticancer activity, antibody-conjugated nano-
particles were shown to discriminate between Her2+ and 
Her2− cells and thus have potential applications in active 
targeted drug delivery and reduction of drug side effects in 
Her2+ breast and ovarian cancers. However, substitution of 
succinic anhydride with a pH-sensitive crosslinker like cis-
aconityl anhydride40–42 or hydrazone bonds43,44 may be taken 
into consideration in future studies to achieve an actively 
targeted vector releasing its cargo drug at its site of action.
CS-DOX nanoparticle
Protein A
Herceptin mAb
Figure 11 Interaction of protein A with antibodies attached to the nanoparticle surface.
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